



(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 37/00 (2006.01)
A61P 35/00 (2006.01) A61P 29/00 (2006.01)

(21) International Application Number:

PCT/EP2021/087338

(22) International Filing Date:

22 December 2021 (22.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20216926.4 23 December 2020 (23.12.2020) EP
2105933.2 26 April 2021 (26.04.2021) GB
21212368.1 03 December 2021 (03.12.2021) EP

(71) Applicant: CANTARGIA AB [SE/SE]; Scheelevägen 27,
SE-223 63 Lund (SE).

(72) Inventors: LIBERG, David; Landsholmagatan 9B, 234
38 Lomma (SE). MILLRUD, Camilla, Rydberg; Idrotts-
gatan 27, 216 14 Limhamn (SE). BIRKEDAL, Gabriel,
Svensson; Dammgatan 11, 243 32 Höör (SE). RATTIK,
Sara; Pilvägen 16, 232 51 Åkarp (SE). SJÖSTRÖM,
Kjell; Rörläggarevägen 16, 227 30 Lund (SE). VON
WACHENFELDT, Karin; Fredsgatan 2A, 222 20 Lund

(SE). GRÖNBERG, Caitriona; Åkervägen 9, 247 45 Tor-
na-Hällestad (SE).

(74) Agent: HOTHERSALL, Pippa, Elizabeth; Potter Clark-
son The Belgrave Centre, Talbot Street, Nottingham Not-
tinghamshire NG1 5GG (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTI-IL1RAP ANTIBODY




Fig. 1

(57) Abstract: The present invention relates to an antibody or antigen-binding fragment thereof with binding specificity for interleukin-1 receptor accessory protein (IL1RAP). Furthermore, it relates to a polynucleotide encoding said antibody, a vector comprising said polynucleotide and a recombinant host cell comprising said polynucleotide or said vector. Further, it relates to a method for producing said antibody or antigen-binding fragment. Further, it relates to a composition comprising said antibody or antigen-binding fragment, said polynucleotide, said vector and/or said host cell. Further, it relates to the said antibody or antigen-binding fragment, said polynucleotide, said vector, said host cell and/or said composition for use in medicine and/or for use in the prevention and/or treatment and/or alleviation and/or detection and/or diagnosis of a disease or disorder susceptible to treatment with an inhibitor of IL-1 α , IL-1 β , IL-33, IL-36 α , IL-36 β and/or IL-36 γ signaling, and/or wherein the disease or disorder is 20 associated with cells expressing IL1RAP.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*